Identification of C21orf59 and ATG2A as novel determinants of renal function-related traits in Japanese by exome-wide association studies by Yamada Yoshiji et al.
Identification of C21orf59 and ATG2A as novel
determinants of renal function-related traits
in Japanese by exome-wide association studies
著者 Yamada Yoshiji, Sakuma Jun, Takeuchi Ichiro,
Yasukochi Yoshiki, Kato Kimihiko, Oguri
Mitsutoshi, Fujimaki Tetsuo, Horibe Hideki,
Muramatsu Masaaki, Sawabe Motoji, Fujiwara
Yoshinori, Taniguchi Yu, Obuchi Shuichi, Kawai
Hisashi, Shinkai Shoji, Mori Seijiro, Arai
Tomio, Tanaka Masashi
journal or
publication title
Oncotarget
volume 8
number 28
page range 45259-45273
year 2017-03
権利 Yamada et al. This is an open-access article
distributed under the terms of the Creative
Commons Attribution License 3.0 (CC BY 3.0),
which permits unrestricted use, distribution,
and reproduction in any medium, provided the
original author and source are credited.
URL http://hdl.handle.net/2241/00151493
doi: 10.18632/oncotarget.16696
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
Oncotarget45259www.impactjournals.com/oncotarget
Identification of C21orf59 and ATG2A as novel determinants 
of renal function-related traits in Japanese by exome-wide 
association studies
Yoshiji Yamada1,2, Jun Sakuma2,3,4, Ichiro Takeuchi2,4,5, Yoshiki Yasukochi1,2, Kimihiko 
Kato1,6, Mitsutoshi Oguri1,7, Tetsuo Fujimaki8, Hideki Horibe9, Masaaki Muramatsu10, 
Motoji Sawabe11, Yoshinori Fujiwara12, Yu Taniguchi12, Shuichi Obuchi13, Hisashi 
Kawai13, Shoji Shinkai14, Seijiro Mori15, Tomio Arai16 and Masashi Tanaka17
1Department of Human Functional Genomics, Advanced Science Research Promotion Center, Mie University, Tsu, Japan
2CREST, Japan Science and Technology Agency, Kawaguchi, Japan
3Computer Science Department, College of Information Science, University of Tsukuba, Tsukuba, Japan
4RIKEN Center for Advanced Intelligence Project, Tokyo, Japan
5Department of Computer Science, Nagoya Institute of Technology, Nagoya, Japan
6Department of Internal Medicine, Meitoh Hospital, Nagoya, Japan
7Department of Cardiology, Kasugai Municipal Hospital, Kasugai, Japan
8Department of Cardiovascular Medicine, Inabe General Hospital, Inabe, Japan
9Department of Cardiovascular Medicine, Gifu Prefectural Tajimi Hospital, Tajimi, Japan
10Department of Molecular Epidemiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
11 Section of Molecular Pathology, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan
12Research Team for Social Participation and Community Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
13Research Team for Promoting Support System for Home Care, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
14Research Team for Social Participation and Health Promotion, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
15Center for Promotion of Clinical Investigation, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
16Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
17Department of Clinical Laboratory, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
Correspondence to: Yoshiji Yamada, email: yamada@gene.mie-u.ac.jp
Keywords: chronic kidney disease, hyperuricemia, glomerular filtration rate, serum uric acid, exome-wide association study
Received: February 12, 2017    Accepted: March 08, 2017    Published: March 30, 2017
Copyright: Yamada et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are 
credited.
ABSTRACT
We have performed exome-wide association studies to identify genetic variants 
that influence renal function-related traits or confer susceptibility to chronic kidney 
disease or hyperuricemia in Japanese. Exome-wide association studies for estimated 
glomerular filtration rate and the serum concentration of creatinine were performed 
with 12,565 individuals, that for the serum concentration of uric acid with 9934 
individuals, and those for chronic kidney disease or hyperuricemia with 5161 
individuals (3270 cases, 1891 controls) or 11,686 individuals (2045 cases, 9641 
controls), respectively. The relation of genotypes of single nucleotide polymorphisms 
to estimated glomerular filtration rate or the serum concentrations of creatinine or 
uric acid was examined by linear regression analysis, and that of allele frequencies 
of single nucleotide polymorphisms to chronic kidney disease or hyperuricemia was 
examined with Fisher’s exact test. The exome-wide association studies revealed that 
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25, seven, and six single nucleotide polymorphisms were significantly (P <1.21 × 10–6)  
associated with estimated glomerular filtration rate or the serum concentrations 
of creatinine or uric acid, respectively, and that 49 and 35 polymorphisms were 
significantly associated with chronic kidney disease or hyperuricemia, respectively. 
Subsequent multivariable logistic regression analysis with adjustment for covariates 
revealed that four and three single nucleotide polymorphisms were related  
(P < 0.05) to chronic kidney disease or hyperuricemia, respectively. Among 
polymorphisms identified in the present study, rs76974938 [C/T (D67N)] of C21orf59 
and rs188780113 [G/A (R478C)] of ATG2A may be novel determinants of estimated 
glomerular filtration rate and chronic kidney disease or of the serum concentration 
of uric acid, respectively.
INTRODUCTION
Chronic kidney disease (CKD) is an important risk 
factor for cardiovascular disease as well as end-stage renal 
disease [1–6]. Genome-wide association studies (GWASs) 
have identified various genes and loci for renal function-
related traits in European ancestry [7–11], African-
American [12, 13], or East Asian [14] populations. A 
recent meta-analysis of GWASs in European ancestry 
populations identified 53 loci that were significantly 
related to estimated glomerular filtration rate (eGFR) [15].
Hyperuricemia is a crucial risk factor for gout, 
a common inflammatory type of arthritis [16, 17], 
cardiovascular disease [18], and cancer [19]. Although 
multiple renal transporters contribute to the maintenance 
of normal circulating uric acid levels by mediating the 
excretion or reabsorption of uric acid in the proximal 
kidney tubules, the underlying mechanisms of such 
homeostasis have not been fully elucidated [20]. The 
heritability of the serum concentration of uric acid has 
been estimated to be 40% [21], suggesting that genetic 
variants contribute to regulation of this parameter by 
influencing uric acid synthesis, excretion, or reabsorption 
[21, 22]. Previous GWASs have identified single 
nucleotide polymorphisms (SNPs) significantly associated 
with the serum uric acid concentration or the prevalence of 
gout [23–29]. A large-scale GWAS in European ancestry 
populations identified 28 loci that influence the serum 
concentration of uric acid [30].
Most genetic variants identified in these various 
previous GWASs were common SNPs with a minor allele 
frequency (MAF) of >5% and a small individual effect 
size. Given that these common SNPs may explain a small 
fraction of the heritability of CKD or hyperuricemia, it 
is expected that low-frequency (0.5% ≤ MAF < 5%) or 
rare (MAF <0.5%) variants with larger effect sizes also 
contribute to the genetic architecture of these conditions 
[31]. Although several polymorphisms have been found 
to be significantly associated with renal function [14] or 
gout [32, 33] in Japanese, genetic variants—including 
low-frequency and rare variants—that influence renal 
function-related traits or contribute to predisposition to 
CKD or hyperuricemia in the Japanese population have 
not been identified definitively.
We have now performed exome-wide association 
studies (EWASs) with the use of exome array-based 
genotyping methods in order to identify SNPs—especially 
low-frequency or rare coding variants with moderate to 
large effect sizes—that influence renal function-related 
traits or confer susceptibility to CKD or hyperuricemia in 
Japanese. Given that most of the known low-frequency 
or rare variants were not included in arrays adopted in 
previous related GWASs, we used Illumina human exome 
arrays that provide coverage of functional SNPs in entire 
exons including low-frequency and rare variants.
RESULTS
EWASs for eGFR and serum concentrations of 
creatinine and uric acid
We examined the relation of genotypes for 41,352 
SNPs that passed quality control to eGFR or the serum 
concentration of creatinine in 12,565 subjects by linear 
regression analysis. Manhattan plots of the EWASs for 
eGFR and the serum creatinine concentration are shown 
in Supplementary Figure 1. After Bonferroni’s correction, 
25 and seven SNPs were significantly [P < 1.21 × 10–6 
(0.05/41,352)] associated with eGFR (Table 1) or the 
serum concentration of creatinine (Table 2), respectively. 
None of these SNPs was associated with both eGFR and 
serum creatinine concentration.
We next examined the relation of genotypes for 41,372 
SNPs that passed quality control to the serum concentration 
of uric acid in 9934 subjects not taking uric acid-lowering 
medications by linear regression analysis. A Manhattan plot 
for this EWAS is also shown in Supplementary Figure 1. 
After Bonferroni’s correction, six SNPs were significantly 
[P < 1.21 × 10–6 (0.05/41,372)] associated with the serum 
concentration of uric acid (Table  3).
EWASs for CKD and hyperuricemia
We performed an EWAS for CKD with 5161 
subjects [3270 individuals with CKD (eGFR of <60 mL 
min–1 1.73 m–2), 1891 controls (eGFR of ≥90 mL min–1 
1.73 m–2)] (Table 4). Age, the frequency of men, body 
mass index, and the prevalence of hypertension, diabetes 
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mellitus, dyslipidemia, and hyperuricemia as well as 
systolic blood pressure, fasting plasma glucose level, 
blood glycosylated hemoglobin (hemoglobin A1c) content, 
and serum concentrations of triglycerides and uric acid 
were greater, whereas the serum concentration of high 
density lipoprotein (HDL)–cholesterol and hemoglobin 
concentration were lower, in subjects with CKD than in 
controls.
We examined the relation of allele frequencies of 
41,352 SNPs to CKD with Fisher’s exact test. A Manhattan 
plot for the EWAS of CKD is shown in Supplementary 
Figure 2. After Bonferroni’s correction, 49 SNPs were 
significantly [P < 1.21 × 10–6 (0.05/41,352)] associated 
with CKD (Supplementary Table 1). The genotype 
distributions for these SNPs were in Hardy-Weinberg 
equilibrium (P > 0.001) among both subjects with CKD 
and controls (Supplementary Table 2).
The relation of the 49 SNPs identified by the EWAS 
to CKD was examined further by multivariable logistic 
regression analysis with adjustment for age, sex, and 
the prevalence of hypertension and diabetes mellitus 
(Supplementary Table 3). Four SNPs (rs707926 of VARS, 
rs76974938 of C21orf59, rs112311672 of HDAC10, 
rs41272317 of ACAD11) were related (P < 0.05 in at 
least one genetic model) to CKD, although there was no 
SNP significantly [P < 2.55 × 10–4 (0.05/196)] associated 
with this condition (Table 5). The minor alleles of these 
SNPs were all risk factors for CKD. The rs76974938 [C/T 
Table 1: The 25 SNPs significantly (P < 1.21 × 10–6) associated with eGFR in the EWAS
Gene dbSNP Nucleotide
(amino acid)
substitutiona
Chromosome:
position
MAF
(%)
P
(genotype)
GGCT rs115910467 C/T (R108H) 7: 30497200 8.2 8.10 × 10–17
COL6A5 rs200982668 G/A (E2501K) 3: 130470894 1.3 2.92 × 10–15
MOB3C rs139537100 C/T (R24Q) 1: 46615006 1.2 1.19 × 10–14
CXCL8 rs188378669 G/T (E31*) 4: 73741568 1.2 1.44 × 10–14
PLCB2 rs200787930 C/T (E1095K) 15: 40289298 1.2 1.80 × 10–14
MARCH1 rs61734696 G/T (Q137K) 4: 164197303 1.2 2.05 × 10–14
VPS33B rs199921354 C/T (R80Q) 15: 91013841 1.2 2.86 × 10–14
TMOD4 rs115287176 G/A (R277W) 1: 151170961 1.2 3.06 × 10–14
TNC rs138406927 C/T (A1096T) 9: 115064848 2.1 3.05 × 10–13
ZNF77 rs146879198 G/A (R340*) 19: 2934109 1.2 4.70 × 10–13
COL6A3 rs146092501 C/T (E1386K) 2: 237371861 1.2 5.91 × 10–13
ADGRL3 rs192210727 G/T (R580I) 4: 61909615 1.3 6.67 × 10–12
C21orf59 rs76974938 C/T (D67N) 21: 32609946 2.4 2.44 × 10–11
KRR1 rs17115182 G/A (P43S) 12: 75508405 7.0 5.31 × 10–11
PTCH2 rs147284320 C/T (V503I) 1: 44828589 2.0 2.28 × 10–9
MUC17 rs78010183 A/T (T1305S) 7: 101035329 1.8 3.82 × 10–9
SCN10A rs77804526 C/T (V1697I) 3: 38698131 0.1 6.83 × 10–8
RFTN1 rs180950245 C/G (N439K) 3: 16323391 0.1 1.63 × 10–7
IGSF9B rs201459911 G/A (A1115V) 11: 133920381 0.7 2.14 × 10–7
IQSEC3 rs12822449 T/C (S283P) 12: 125856 0.2 3.51 × 10–7
CCDC186 rs79637542 C/T (A771T) 10: 114127543 0.2 5.10 × 10–7
PRAMEF12 rs199576535 G/A (V341I) 1: 12777168 1.0 5.91 × 10–7
rs1873059 G/A 11: 45519053 47.4 6.95 × 10–7
PTCHD3 rs77473776 T/G (K186Q) 10: 27413695 30.6 9.41 × 10–7
L1TD1 rs2886644 C/T (T613I) 1: 62210612 11.0 1.04 × 10–6
The relation of genotypes of SNPs to eGFR was evaluated by linear regression analysis. 
aMajor allele/minor allele.
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(D67N)] SNP of C21orf59 was associated with both eGFR 
and CKD.
We next performed an EWAS for hyperuricemia with 
11,686 subjects (2045 individuals with hyperuricemia, 
9641 controls), the characteristics of whom are shown 
in Table 6. Age, the frequency of men, body mass index, 
and the prevalence of smoking, hypertension, diabetes 
mellitus, dyslipidemia, and CKD were greater in subjects 
with hyperuricemia than in controls.
We examined the relation of allele frequencies 
of 41,372 SNPs to hyperuricemia with Fisher’s 
exact test. A Manhattan plot for the EWAS is shown 
in Supplementary Figure 2. After Bonferroni’s 
correction, 35 SNPs were significantly [P < 1.21 × 
10–6 (0.05/41,372)] associated with hyperuricemia 
(Supplementary Table 4). The genotype distributions 
for these SNPs were in Hardy-Weinberg equilibrium (P 
> 0.001) among both subjects with hyperuricemia and 
controls (Supplementary Table 5).
The relation of the 35 SNPs identified by the EWAS 
to hyperuricemia was examined further by multivariable 
logistic regression analysis with adjustment for age and 
sex (Supplementary Table 6). Three SNPs (rs115445569 
of ACOT11, rs116911833 of TRIM7, rs60854092 of 
NOTCH2) were related (P < 0.05 in at least one genetic 
model) to hyperuricemia, although there was no SNP 
significantly [P < 3.57 × 10–4 (0.05/140)] associated with 
this condition (Table 7). The minor T and A alleles of 
rs115445569 and rs116911833, respectively, were risk 
factors for hyperuricemia, whereas the minor A allele of 
rs60854092 was protective against hyperuricemia.
Relation of identified SNPs to eGFR or serum 
concentrations of creatinine or uric acid
We examined the relations of genotypes for SNPs 
identified in the various EWASs to eGFR or serum 
concentrations of creatinine or uric acid by one-way analysis of 
Table 2: The seven SNPs significantly (P < 1.21 × 10–6) associated with the serum concentration of creatinine in 
the EWAS
Gene dbSNP Nucleotide
(amino acid)
substitutiona
Chromosome:
position
MAF
(%)
P
(genotype)
CAT rs139421991 G/A (R320Q) 11: 34456720 0.3 6.34 × 10–11
EIF2AK4 rs35602605 G/T (G1306C) 15: 40016658 0.1 1.60 × 10–10
SP7 rs188929035 G/A (A5V) 12: 53329374 0.4 7.10 × 10–9
CSMD2 rs148658404 G/A (S3311F) 1: 33533855 0.7 3.89 × 10–7
SASH1 rs199980930 G/A 6: 148546146 0.1 4.57 × 10–7
RNF123 rs35620248 G/A (R387Q) 3: 49700521 0.3 1.20 × 10–6
ALG12 rs3922872 T/C (I393V) 22: 49904240 5.5 1.20 × 10–6
The relation of genotypes of SNPs to the serum concentration of creatinine was evaluated by linear regression analysis. 
aMajor allele/minor allele.
Table 3: The six SNPs significantly (P < 1.21 × 10–6) associated with the serum concentration of uric acid in 
the EWAS
Gene dbSNP Nucleotide
(amino acid)
substitutiona
Chromosome:
position
MAF
(%)
P
(genotype)
SLC22A12 rs121907892 G/A (W258*) 11: 64593747 2.4 1.23 × 10–130
ATG2A rs188780113 G/A (R478C) 11: 64911072 3.3 1.00 × 10–39
SLC22A12 rs505802 G/A 11: 64589600 17.5 1.27 × 10–24
CDC42BPG rs55975541 G/A (R1237W) 11: 64829729 16.5 3.90 × 10–13
SLC2A9 rs3775948 G/C 4: 9993558 42.4 1.40 × 10–12
SLC2A9 rs3733591 T/C (H265R) 4: 9920506 28.7 1.01 × 10–6
The relation of genotypes of SNPs to the serum concentration of uric acid was evaluated by linear regression analysis 
aMajor allele/minor allele.
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Table 4: Characteristics of the 5161 study subjects in the EWAS for CKD
Characteristic CKD Controls P
No. of subjects 3270 1891
Age (years) 69.9 ± 10.9 53.2 ± 13.4 <0.0001
Sex (male/female, %) 61.4/38.6 52.6/47.4 <0.0001
Body mass index (kg/m2) 23.5 ± 3.5 23.0 ± 3.7 <0.0001
Hypertension (%) 75.3 43.2 <0.0001
Systolic blood pressure (mmHg) 140 ± 26 128 ± 24 <0.0001
Diastolic blood pressure (mmHg) 77 ± 15 76 ± 14 0.0111
Diabetes mellitus (%) 38.4 25.4 <0.0001
Fasting plasma glucose (mmol/L) 6.76 ± 2.93 6.39 ± 2.81 <0.0001
Blood hemoglobin A1c (%) 6.09 ± 1.31 6.06 ± 1.47 <0.0001
Dyslipidemia (%) 69.0 56.4 <0.0001
Serum triglycerides (mmol/L) 1.58 ± 0.99 1.34 ± 1.15 <0.0001
Serum HDL-cholesterol (mmol/L) 1.37 ± 0.45 1.54 ± 0.47 <0.0001
Serum LDL-cholesterol (mmol/L) 3.06 ± 0.90 3.06 ± 0.85 0.7907
Hyperuricemia (%) 37.0 7.9 <0.0001
Serum uric acid (μmol/L) 374 ± 105 292 ± 84 <0.0001
Hemoglobin (g/dL) 13.3 ± 1.6 13.6 ± 1.5 <0.0001
Blood urea nitrogen (mmol/L) 7.54 ± 4.41 4.67 ± 1.39 <0.0001
Serum creatinine (μmol/L) 130 ± 161 51 ± 9 <0.0001
eGFR (mL min–1 1.73 m–2) 47.4 ± 13.2 102.9 ± 18.9 <0.0001
Quantitative data are means ± SD and were compared between subjects with CKD and controls with the Mann-whitney 
u test. Categorical data were compared between the two groups with the pearson’s chi-square test. Based on Bonferroni’s 
correction, a P value of <0.0028 (0.05/18) was considered statistically significant. HDL, high density lipoprotein; LDL, low 
density lipoprotein.
Table 5: Relation of SNPs to CKD as determined by multivariable logistic regression analysis
SNP Dominant Recessive Additive 1 Additive 2
P OR  
(95% CI)
P OR  
(95% CI)
P OR  
(95% CI)
P OR  
(95% CI)
rs707926 G/A 0.4239 0.0042 1.54  (1.14–2.08) 0.9753 0.0052
1.53  
(1.14–2.09)
rs76974938 C/T (D67N) 0.0420 1.52 (1.00–2.42) ND 0.0420
1.52  
(1.00–2.42) ND
rs112311672 G/A (T398M) 0.0492 3.33 (1.00–
13.35)
ND 0.0492 3.33  
(1.00–13.35)
ND
rs41272317 C/A 0.2694 0.0220 1.11 × 10
8 
(ND) 0.2094 0.0224
1.10 × 108 
(ND)
Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension 
and diabetes mellitus. Based on Bonferroni’s correction, a P value of <2.55 × 10–4 (0.05/196) was considered statistically 
significant. OR, odds ratio; CI, confidence interval; ND, not determined.
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variance (ANOVA). The 25 SNPs identified in the EWAS for 
eGFR were all significantly [P < 0.0018 (0.05/28)] associated 
with eGFR (Table 8). Among the four SNPs identified in the 
analysis of CKD, only rs76974938 was significantly related 
to eGFR. The seven SNPs identified in the EWAS for serum 
creatinine concentration were all significantly [P < 0.0045 
(0.05/11)] related to the serum concentration of creatinine 
(Table 9). Among the four SNPs identified in the analysis of 
CKD, only rs76974938 was significantly related to the serum 
concentration of creatinine. The six SNPs identified in the 
EWAS for serum uric acid concentration were all significantly 
[P < 0.0056 (0.05/9)] related to the serum concentration of 
uric acid, but the three SNPs identified in the analysis of 
hyperuricemia were not (Table 10).
Relation of SNPs identified in the present study 
to phenotypes previously examined in GWASs
We examined the relation of genes, chromosomal 
loci, and SNPs identified in the present study to 
phenotypes previously probed in GWASs with data 
available in public databases [GWAS Catalog (http://
www.ebi.ac.uk/gwas) and GWAS Central (http://www.
gwascentral.org/browser)]. Chromosomal region 11p11.2 
and SASHI were previously shown to be susceptibility loci 
for CKD [15] or diabetic nephropathy [34], respectively. 
In addition, MARCH1 and RFTN1 were previously shown 
to be related to urinary uromodulin [35] or serum uric acid 
[36] levels, respectively. The remaining 31 SNPs identified 
Table 6: Characteristics of the study subjects in the EWAS for hyperuricemia
Characteristic Hyperuricemia Controls P
No. of subjects 2045 9641
Age (years) 59.6 ± 12.2 58.3 ± 13.2 <0.0001
Sex (male/female, %) 86.7/13.4 52.9/47.1 <0.0001
Body mass index (kg/m2) 24.3 ± 3.7 23.1 ± 3.4 <0.0001
Current or former smoker 
(%) 53.7 34.7 <0.0001
Hypertension (%) 68.9 47.2 <0.0001
Diabetes mellitus (%) 31.5 23.0 <0.0001
Dyslipidemia (%) 77.6 58.4 <0.0001
CKD (%) 44.8 17.9 <0.0001
Serum uric acid (μmol/L) 453 ± 83 296 ± 67 <0.0001
Quantitative data are means ± SD and were compared between subjects with hyperuricemia and controls with the  
Mann-whitney u test. Categorical data were compared between the two groups with the pearson’s test chi-square test. Based 
on Bonferroni’s correction, a P value of <0.0056 (0.05/9) was considered statistically significant.
Table 7: Relation of SNPs to hyperuricemia as determined by multivariable logistic regression analysis
SNP Dominant Recessive Additive 1 Additive 2
P OR  
(95% CI)
P OR  
(95% CI)
P OR  
(95% CI)
P OR 
(95% CI)
rs115445569 C/T (R64Q) 0.0228 1.43  
(1.05–1.93)
0.5153 0.0266 1.42  (1.04–1.92) 0.5114
rs116911833 G/A (T80M) 0.2547 0.0331 7.21 (1.19–43.73) 0.1557 0.0337
7.15  
(1.18–43.43)
rs60854092 T/A (F1689I) 0.0377 0.83 (0.69–0.99) 0.4797 0.0455
0.84  
(0.70–1.00) 0.4628
Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni’s correction, 
a P value of <3.57 × 10–4 (0.05/140) was considered statistically significant.
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Table 8: Relation of SNPs identified in the present study to eGFR
SNP eGFR (mL min–1 1.73 m–2) P
Associated with eGFR and CKD
rs76974938 C/T (D67N) CC CT
73.2 ± 21.3 67.2 ± 13.1 2.44 × 10-11
Associated with eGFR
rs115910467 C/T (R108H) CC CT
73.2 ± 21.2 66.3 ± 13.9 8.10 × 10-17
rs200982668 G/A (E2501K) GG GA
72.0 ± 20.6 80.8 ± 15.5 2.92 × 10-15
rs139537100 C/T (R24Q) CC CT
72.0 ± 20.6 80.8 ± 15.5 1.19 × 10-14
rs188378669 G/T (E31*) GG GT
72.0 ± 20.6 80.9 ± 15.5 1.44 × 10-14
rs200787930 C/T (E1095K) CC CT
72.0 ± 20.6 80.8 ± 15.5 1.80 × 10-14
rs61734696 G/T (Q137K) GG GT
72.0 ± 20.6 80.8 ± 15.4 2.05 × 10-14
rs199921354 C/T (R80Q) CC CT
72.0 ± 20.6 80.8 ± 15.5 2.86 × 10-14
rs115287176 G/A (R277W) GG GA
72.0 ± 20.6 80.8 ± 15.4 3.06 × 10-14
rs138406927 C/T (A1096T) CC CT
73.1 ± 21.3 66.2 ± 14.5 3.05 × 10-13
rs146879198 G/A (R340*) GG GA
72.0 ± 20.6 80.5 ± 15.4 4.70 × 10-13
rs146092501 C/T (E1386K) CC CT
72.0 ± 20.6 80.4 ± 15.5 5.91 × 10-13
rs192210727 G/T (R580I) GG GT TT
72.0 ± 20.6 79.6 ± 16.0 84.6 ± 13.6 5.64 × 10-11
rs17115182 G/A (P43S) GG GA
73.2 ± 21.3 66.7 ± 13.3 5.31 × 10-11
rs147284320 C/T (V503I) CC CT
73.4 ± 17.5 78.6 ± 15.9 2.28 × 10-9
rs78010183 A/T (T1305S) AA AT
72.1 ± 20.7 77.4 ± 15.3 3.82 × 10-9
rs77804526 C/T (V1697I) CC CT TT
72.2 ± 20.0 100.0 ± 116.9 65.1 9.50 × 10-9
rs180950245 C/G (N439K) CC CG
72.2 ± 20.0 92.5 ± 99.1 1.23 × 10-7
rs201459911 G/A (A1115V) GG GA
72.4 ± 20.5 65.1 ± 22.0 2.14 × 10-7
rs12822449 T/C (S283P) TT TC
70.5 ± 21.7 50.6 ± 17.8 3.51 × 10-7
rs79637542 C/T (A771T) CC CT
72.2 ± 20.0 86.2 ± 71.1 5.10 × 10-7
rs199576535 G/A (V341I) GG GA
72.1 ± 20.6 78.2 ± 14.1 5.91 × 10-7
rs1873059 G/A GG GA AA
71.2 ± 19.4 72.2 ± 21.2 73.8 ± 20.1 3.45 × 10-6
rs77473776 T/G (K186Q) TT TG GG
72.9 ± 21.7 72.1 ± 19.5 69.0 ± 15.0 2.89 × 10-7
rs2886644 C/T (T613I) CC CT TT
73.3 ± 21.4 70.9 ± 18.6 68.3 ± 18.1 6.53 × 10-6
Associated with CKD
rs707926 G/A GG GA AA
72.3 ± 20.4 72.6 ± 20.9 70.5 ± 18.3 0.0255
rs112311672 G/A (T398M) GG GA
72.3 ± 20.5 72.4 ± 15.1 0.9683
rs41272317 C/A CC CA AA
72.3 ± 20.5 72.6 ± 20.2 73.5 ± 5.0 0.8680
Data were compared among genotypes by one-way ANOVA. Based on Bonferroni’s correction, P values of <0.0018 (0.05/28) were considered 
statistically significant and are shown in bold.
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in the present study as being related to eGFR, the serum 
creatinine concentration, or CKD were not previously 
identified as genetic determinants of renal function-related 
traits or CKD (Supplementary Table 7). SLC22A12 [27, 
37], CDC42BPG [29], and SLC2A9 [32, 37–39] were 
previously implicated as determinants of the serum 
concentration of uric acid or gout, whereas the remaining 
four SNPs identified in the present study as being related 
to the serum concentration of uric acid or hyperuricemia 
were not previously found to influence serum uric acid 
levels, hyperuricemia, or gout (Supplementary Table 8).
DISCUSSION
We have now shown that rs76974938 [C/T (D67N)] 
of C21orf59 was associated with eGFR and CKD. Twenty-
four additional SNPs and seven SNPs were significantly 
related to eGFR or the serum concentration of creatinine, 
respectively. Among these genes and loci, 11p11.2 and 
SASH1 were previously identified as susceptibility loci 
for CKD [15] or diabetic nephropathy [34], respectively. 
MARCH1 and RFTN1 were also previously shown to 
be related to urinary uromodulin [35] or serum uric 
Table 9: Relation of SNPs identified in the present study to serum creatinine concentration
SNP Serum creatinine (μmol/L) P
Associated with serum creatinine
rs139421991 G/A (R320Q) GG GA
76.7 ± 76.7 129.9 ± 222.4 6.34 × 10-11
rs35602605 G/T (G1306C) GG GT TT
78.1 ± 81.7 200.2 ± 354.0 88.4 4.50 × 10-11
rs188929035 G/A (A5V) GG GA AA
78.1 ± 81.1 98.7 ± 161.1 1502.8 <1.0 × 10-23
rs148658404 G/A (S3311F) GG GA
77.9 ± 78.7 110.0 ± 216.2 3.89 × 10-7
rs199980930 G/A GG GA
78.1 ± 82.1 151.1 ± 238.2 4.57 × 10-7
rs35620248 G/A (R387Q) GG GA
78.1 ± 81.2 126.0 ± 242.6 1.23 × 10-6
rs3922872 T/C (I393V) TT TC CC
77.2 ± 76.9 87.7 ± 118.5 106.3 ± 204.8 6.68 × 10-6
Associated with CKD
rs707926 G/A GG GA AA
77.9 ± 81.9 79.2 ± 86.0 77.2 ± 74.4 0.6246
rs112311672 G/A (T398M) GG GA
78.4 ± 83.3 68.4 ± 14.4 0.3146
rs41272317 C/A CC CA AA
78.3 ± 83.1 78.2 ± 83.3 69.7 ± 21.7 0.9127
rs76974938 C/T (D67N) CC CT
80.1 ± 89.3 66.8 ± 16.3 0.0003
Data were compared among genotypes by one-way ANOVA. Based on Bonferroni’s correction, P values of <0.0045 
(0.05/11) were considered statistically significant and are shown in bold.
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acid [36] levels, respectively. The remaining 21 and six 
SNPs identified in our study are thus potential novel 
loci related to eGFR or to the serum concentration of 
creatinine, respectively, in Japanese. We also identified 
three additional SNPs related to CKD, all of which are 
candidates for novel susceptibility loci for this condition.
We also found that rs121907892 [G/A (W258*)] 
and rs505802 (G/A) of SLC22A12, rs188780113 [G/A 
(R478C)] of ATG2A, rs55975541 [G/A (R1237W)] 
of CDC42BPG, and rs3775948 (G/C) and rs3733591 
[T/C (H265R)] of SLC2A9 were significantly associated 
with the serum concentration of uric acid. In addition, 
rs115445569 [C/T (R64Q)] of ACOT11, rs116911833 
[G/A (T80M)] of TRIM7, and rs60854092 [T/A (F1689I) 
of NOTCH2 were related to hyperuricemia, although 
the genotypes of these SNPs were not related to the 
serum concentration of uric acid. Among these genes, 
SLC22A12 [27, 37], CDC42BPG [29], and SLC2A9 [32, 
37–39] were previously found to be related to serum uric 
acid levels or gout. The remaining four genes (ATG2A, 
ACOT11, TRIM7, and NOTCH2) may be novel loci that 
influence the serum concentration of uric acid or confer 
susceptibility to hyperuricemia.
SNPs associated with renal function
The chromosome 21 open reading frame 59 gene 
(C21orf59) is located at chromosomal region 21q22.11 
(NCBI Gene, https://www.ncbi.nlm.nih.gov/gene) 
and is widely expressed including in the kidney (The 
Human Protein Atlas, http://www.proteinatlas.org). 
Studies in zebrafish and Xenopus have revealed that the 
protein encoded by C21orf59 activates the motility and 
polarization of cilia and thereby contributes to cilia-
mediated processes such as the generation of fluid flow 
[40]. The primary cilium is a microtubule-based organelle. 
Impairment of ciliary function can result in polycystic 
kidney disease [41]. C21orf59 contributes to the assembly 
Table 10: Relation of SNPs identified in the present study to the serum concentration of uric acid
SNP Serum uric acid (μmol/L) P
Associated with serum uric acid
rs121907892 G/A (W258*) GG GA AA
333 ± 93 230 ± 79 50 ± 18 <1.0 × 10-23
rs188780113 G/A (R478C) GG GA AA
331 ± 93 283 ± 103 197 ± 105 <1.0 × 10-23
rs505802 G/A GG GA AA
334 ± 92 318 ± 98 291 ± 97 <1.0 × 10-23
rs55975541 G/A (R1237W) GG GA AA
332 ± 94 319 ± 95 306 ± 111 3.62 × 10-12
rs3775948 G/C GG GC CC
335 ± 93 329 ± 94 314 ± 97 1.37 × 10-12
rs3733591 T/C (H265R) TT TC CC
324 ± 94 331 ± 96 339 ± 93 6.36 × 10-6
Associated with hyperuricemia
rs115445569 C/T (R64Q) CC CT TT
328 ± 95 341 ± 101 345 ± 170 0.1012
rs116911833 G/A (T80M) GG GA AA
328 ± 95 324 ± 89 352 ± 109 0.5779
rs60854092 T/A (F1689I) TT TA AA
328 ± 94 325 ± 98 322 ± 121 0.5501
Data were compared among genotypes by one-way ANOVA. Based on Bonferroni’s correction, P values of <0.0056 
(0.05/9) were considered statistically significant and are shown in bold.
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of dynein arms in motile cilia, with mutations in C21orf59 
having been found to cause ciliary dyskinesia [42]. 
We have now shown that rs76974938 [C/T (D67N)] of 
C21orf59 was significantly associated with eGFR and 
CKD, with the minor T allele representing a risk factor 
for CKD. Given that C21orf59 is implicated in cilium 
function and that cilia serve as mechanosensors to detect 
fluid flow in the lumen of renal tubules, the association of 
C21orf59 with eGFR and CKD might reflect an effect of 
this gene on renal tubular function.
In a previous GWAS for individuals of European 
ancestry [9], the MAFs of CKD-associated SNPs were 
13% to 27%, their effect sizes (percentage change in serum 
creatinine levels) were –1.0% to 1.1%, and the allele 
odds ratios (ORs) for CKD were 0.84 to 1.07. Another 
GWAS performed with subjects of European ancestry [10] 
identified eGFR-associated SNPs whose MAFs were 5% 
to 50% and ORs for CKD were 0.80 to 1.19. In a meta-
analysis of GWASs with a total of 137,629 individuals of 
European ancestry, the MAFs of eGFR-associated SNPs 
were 10% to 47% [15], and in a similar analysis with a 
total of 71,149 East Asian individuals the MAFs of kidney 
function–associated SNPs were 11% to 43% [14].
In the present study, rs76974938 of C21orf59 had 
a MAF of 2.4% and an allele OR of 4.52 for CKD, and it 
showed a difference in eGFR of 6.0 mL min–1 1.73 m–2 or 
in the serum concentration of creatinine of 13.3 μmol/L 
among genotypes. This SNP was thus a low-frequency 
variant with a moderate effect size. For the remaining 
24 SNPs [MAF, difference in eGFR (mL min–1 1.73 m–
2) among genotypes] identified in the EWAS of eGFR, 
rs77804526 (0.1%, 27.8), rs180950245 (0.1%, 20.3), 
rs12822449 (0.2%, 19.9), and rs79637542 (0.2%, 14.0) 
were rare variants with a large effect size; rs200982668 
(1.3%, 8.8), rs139537100 (1.2%, 8.8), rs188378669 
(1.2%, 8.9), rs200787930 (1.2%, 8.8), rs61734696 (1.2%, 
8.8), rs199921354 (1.2%, 8.8), rs115287176 (1.2%, 
8.8), rs138406927 (2.1%, 6.9), rs146879198 (1.2%, 
8.5), rs146092501 (1.2%, 8.4), rs192210727 (1.3%, 
7.6), rs147284320 (2.0%, 5.2), rs78010183 (1.8%, 5.3), 
rs201459911 (0.7%, 7.3), and rs199576535 (1.0%, 6.1) 
were low-frequency variants with a moderate effect size; 
and rs115910467 (8.2%, 6.9), rs17115182 (7.0%, 6.5), 
rs1873059 (47.4%, 2.6), rs77473776 (30.6%, 3.9), and 
rs2886644 (11.0%, 5.0) were common variants with a 
low to moderate effect size (Supplementary Figure 3A). 
In the case of the seven SNPs [MAF, difference in serum 
creatinine concentration (μmol/L) among genotypes] 
identified in the EWAS for serum creatinine concentration, 
rs139421991 (0.3%, 53.2), rs35602605 (0.1%, 122.1), 
rs188929035 (0.4%, 20.6), rs199980930 (0.1%, 73.0), 
and rs35620248 (0.3%, 47.9) were rare variants with a 
moderate to large effect size; rs148658404 (0.7%, 32.1) 
was a low-frequency variant with a moderate effect size; 
and rs3922872 (5.5%, 10.5) was a common variant with a 
small effect size (Supplementary Figure 3B).
SNPs associated with the serum concentration of 
uric acid
The autophagy related 2A gene (ATG2A) is 
located at chromosomal region 11q13.1 (NCBI Gene) 
and is expressed in various organs including the 
kidney and gastrointestinal tract (The Human Protein 
Atlas). Autophagy is an intracellular process in which 
cytoplasmic material is enveloped by authophagosomes 
and delivered to lysosomes for degradation [43]. 
Mammalian ATG2A is localized to the autophagosome 
membrane as well as to lipid droplets. Knockdown 
of both ATG2A and ATG2B in adipocytes results in 
an increase in the size and number of lipid droplets 
and in their clustering. The mammalian proteins thus 
promote autophagosome formation [44]. Activation 
of neutrophils in gout promotes the formation of 
proinflammatory neutrophil extracellular traps, a process 
linked to autophagy-related signaling and interleukin-
1β activity [45]. We have now shown that rs188780113 
[G/A (R478C)] of ATG2A was significantly associated 
with the serum concentration of uric acid, with the 
minor A allele being related to decreased uric acid 
levels. Although the molecular mechanism underlying 
this association remains unclear, it might be attributable 
to the role of ATG2A in autophagy-related metabolic 
processes.
The acyl-CoA thioesterase 11 gene (ACOT11) is 
located at chromosomal region 1p32.3 (NCBI Gene) 
and is expressed in various organs including the kidney 
and gastrointestinal tract (The Human Protein Atlas). 
Mammalian acyl-CoA thioesterases catalyze the 
conversion of activated fatty acids to the corresponding 
nonesterified fatty acid and coenzyme A [46]. ACOT11 
mRNA levels were increased in mouse brown adipose 
tissue by cold exposure and decreased by warm 
temperatures as well as were higher in this tissue of 
obesity-resistant mice than in obesity-prone mice [47]. 
ACOT11 functions to reduce energy consumption and 
conserve calories, also suggestive of a role in obesity 
[48]. In nutritional excess, the overproduction of free fatty 
acids by ACOT11 induces insulin resistance, leading to 
increases in inflammation and endoplasmic reticulum 
stress [48]. We have now shown that rs115445569 [C/T 
(R64Q)] of ACOT11 was related to hyperuricemia, with 
the minor T allele representing a risk factor this condition. 
The association of ACOT11 with hyperuricemia might 
reflect the fact that ACOT11 is implicated in adipose 
tissue metabolism and that obesity is a risk factor for 
hyperuricemia.
The tripartite motif containing 7 gene (TRIM7) is 
located at chromosomal region 5q35.3 (NCBI Gene) 
and is widely expressed including in the kidney and 
gastrointestinal tract (The Human Protein Atlas). A 
family of tripartite motif (TRIM) proteins comprises >70 
members and contributes to various biological processes 
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[49–54]. TRIM7 is a glycogenin-interacting protein that 
contributes to cellular glucose metabolism [55]. We have 
now shown that rs116911833 [G/A (T80M)] of TRIM7 
was significantly associated with hyperuricemia, with the 
minor A allele representing a risk factor for this condition. 
Given the potential role of TRIM7 in diverse cellular 
processes, the molecular mechanism underlying this 
association remains unclear.
The NOTCH2 gene is located at chromosomal 
region 1p12 (NCBI Gene) and is ubiquitously expressed 
including in the kidney and gastrointestinal tract (The 
Human Protein Atlas). Notch2 functions as a receptor 
for membrane-bound ligands and is implicated in the 
development of vessels, kidney, and liver [56]. It also 
contributes to skeletal homeostasis, osteoblastogenesis, 
and osteoclastogenesis [57]. Mutations in NOTCH2 that 
result in the production of a stable truncated protein 
are responsible for Hajdu-Cheney syndrome, which is 
characterized by defects in craniofacial development, 
osteoporosis with fractures, acro-osteolysis, neurological 
complications, cardiovascular defects, and polycystic 
kidneys [58]. Mutations of NOTCH2 also cause Alagille 
syndrome [59]. NOTCH2 was shown to be a susceptibility 
locus for type 2 diabetes mellitus [60]. We have now 
shown that rs60854092 [T/A (F1689I)] of NOTCH2 was 
significantly associated with hyperuricemia, with the 
minor A allele being protective against this condition. 
Given that insulin resistance may be a common underlying 
mechanism contributing to type 2 diabetes mellitus and 
hyperuricemia [61], the association of NOTCH2 with 
hyperuricemia might reflect the effect of this gene on type 
2 diabetes.
In a previous large-scale GWAS for serum uric 
acid concentration [30], the MAFs of related SNPs were 
11% to 49% and their effect sizes ranged from –10.9 
to 22.2 μmol/L (–0.184 to 0.373 mg/dL). In our study, 
among the six SNPs significantly related to the serum 
concentration of uric acid, the MAF (difference in serum 
uric acid level among genotypes) of rs121907892 or 
rs188780113 was 2.4% (283 μmol/L) and 3.3% (134 
μmol/L), respectively. These SNPs were thus low-
frequency variants with a large effect size. The MAF 
(difference in serum uric acid level among genotypes) 
of the remaining four SNPS (rs505802, rs55975541, 
rs3775948, and rs3733591) was 17.5% (43 μmol/L), 
16.5% (26 μmol/L), 42.4% (21 μmol/L), and 28.7% 
(15 μmol/L), respectively. These SNPs were thus 
common variants with a small to moderate effect size 
(Supplementary Figure 4). The MAFs (allele ORs) of 
the three SNPs related to hyperuricemia (rs115445569, 
rs116911833, and rs60854092) were 1.1% (1.51), 2.0% 
(1.21), and 4.6% (0.85), respectively. These SNPs were 
thus low-frequency variants with a small to moderate 
effect size.
Study limitations
There are several limitations in the present study. (i) 
Although an eGFR is affected by body weight, especially 
skeletal muscle mass, the formula for eGFR used in the 
present study did not include body weight. (ii) We did not 
obtain information on microhematuria or microalbuminuria 
in controls. Information by detailed clinical examination 
including renal biopsy was not obtained in most subjects, 
given that such diagnostic procedures were not considered 
feasible for an epidemiological study whose subjects were 
recruited from the general population. (iii) Some patients 
were diagnosed for CKD with an eGFR <60 mL min–1 
1.73 m–2 at one point of examination. Dehydration status 
in such subjects was not examined. Data for the rate of 
GFR fall in a long-term follow up were not available for 
the present study subjects. (iv) Given that our results 
were not replicated, they will require validation in other 
subject panels or ethnic groups. (v) It is possible that SNPs 
identified in the present study are in linkage disequilibrium 
with other polymorphisms in nearby genes that are actually 
responsible for the observed associations. (vi) Three SNPs 
associated with CKD were not related to eGFR or to the 
serum concentration of creatinine. In addition, the three 
SNPs associated with hyperuricemia were not related 
to the serum concentration of uric acid. It is possible that 
these discrepancies are attributable to the effects of medical 
treatment. (vii) The molecular mechanisms of the observed 
associations remain to be determined.
CONCLUSIONS
In conclusion, we have identified rs76974938 [C/T 
(D67N)] of C21orf59 as a novel genetic determinant of 
renal function and CKD. We identified an additional 21 
and six SNPs as novel determinants of eGFR or the serum 
concentration of creatinine, respectively, as well as an 
additional three SNPs as novel candidate susceptibility 
loci for CKD. We also identified rs188780113 [G/A 
(R478C)] of ATG2A as a novel determinant of the serum 
concentration of uric acid as well as rs115445569 of 
ACOT11, rs116911833 of TRIM7, and rs60854092 
of NOTCH2 as potential novel susceptibility loci 
for hyperuricemia. Analysis of these SNPs may be 
informative for assessment of the genetic risk for CKD or 
hyperuricemia in Japanese.
MATERIALS AND METHODS
Study subjects
For the EWASs of eGFR or the serum concentration 
of creatinine, a total of 12,565 Japanese was examined. A 
total of 9934 subjects who did not take uric acid-lowering 
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medications was examined in the EWAS for the serum 
concentration of uric acid. In the EWASs for CKD or 
hyperuricemia, 5161 individuals (3270 subjects with 
CKD, 1891 controls) or 11,686 individuals (2045 subjects 
with hyperuricemia, 9641 controls) were examined, 
respectively. Study subjects were recruited as previously 
described [62].
Glomerular filtration rate was estimated with the 
use of the simplified prediction equation derived from the 
modified version of that described in the Modification of 
Diet in Renal Disease (MDRD) Study, as proposed by the 
Japanese Society of Nephrology [63]: eGFR (mL min–1 
1.73 m–2) = 194 × [age (years)]–0.287 × [serum creatinine 
(mg/dL)]–1.094 × [0.739 if female]. The National Kidney 
Foundation–Kidney Disease Outcomes Quality Initiative 
guidelines recommend a diagnosis of CKD if eGFR is 
<60 mL min–1 1.73 m–2 [4]. Nonlinear relations between 
GFR and the risk of adverse events, such as death, 
cardiovascular events, and hospitalization, have been 
demonstrated, with an increased risk being associated with 
an eGFR of <60 mL min–1 1.73 m–2 and the risk markedly 
rising further when values fall below 45 mL min–1 1.73 
m–2 [64]. We thus adopted the criterion of an eGFR of <60 
mL min–1 1.73 m–2 (actual range, 2.5 to 59.9 mL min–1 1.73 
m–2) for the diagnosis of CKD in the present study. The 
control individuals for the EWAS of CKD had an eGFR 
of ≥90 mL min–1 1.73 m–2 (actual range, 90 to 584.9 mL 
min–1 1.73 m–2) and did not appear to have functional or 
structural abnormalities of the kidneys or a history of renal 
disease.
Hyperuricemia was defined as a serum uric acid 
concentration of >416 μmol/L (actual range, 422 to 1172 
μmol/L) or the taking of uric acid-lowering medication. 
Individuals taking drugs that may cause secondary 
hyperuricemia were excluded. The control individuals 
for the EWAS of hyperuricemia had a serum uric acid 
concentration of ≤416 μmol/L (actual range, 36 to 416 
μmol/L) and had no history of hyperuricemia or gout or of 
taking uric acid-lowering medication. Autopsy cases were 
excluded from controls for the EWASs of both CKD and 
hyperuricemia.
The study protocol complied with the Declaration 
of Helsinki and was approved by the Committees on the 
Ethics of Human Research of Mie University Graduate 
School of Medicine, Hirosaki University Graduate School 
of Medicine, Tokyo Metropolitan Institute of Gerontology, 
and participating hospitals. Written informed consent was 
obtained from each participant or families of the deceased 
subjects.
EWASs
Methods for collection and extraction of genomic 
DNA samples were described previously [62]. All 
EWASs (Supplementary Figure 5) were performed 
with the use of the HumanExome-12 v1.1 or v1.2 DNA 
Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip 
(Illumina, San Diego, CA, USA). Detailed information of 
these exome arrays and methods of quality control were 
described previously [62]. Totals of 41,352 SNPs (eGFR, 
serum creatinine concentration, CKD) or 41,372 SNPs 
(serum uric acid concentration, hyperuricemia) that passed 
quality control were analyzed.
Statistical analysis
The relation of genotypes of SNPs to eGFR or 
the serum concentrations of creatinine or uric acid in 
the EWAS was evaluated by linear regression analysis. 
In comparisons of characteristics between subjects with 
CKD or hyperuricemia and corresponding controls, 
quantitative data were compared between two groups by 
the Mann–Whitney U-test, given that variables showed 
skewed distribution (P <0.01 by the Kolmogorov-Smirnov 
and Lilliefors test). Categorical data were compared 
between two groups by the Pearson’s chi-square test. 
Allele frequencies were estimated by the gene counting 
method, and Fisher’s exact test was applied to identify 
departure from Hardy-Weinberg equilibrium. The relation 
of allele frequencies of SNPs to CKD or hyperuricemia 
in the EWAS was examined with Fisher’s exact test. To 
compensate for multiple comparisons of genotypes with 
eGFR or the serum concentrations of creatinine or uric 
acid, or of allele frequencies with CKD or hyperuricemia, 
we applied Bonferroni’s correction for statistical 
significance of association. Given that 41,352 or 41,372 
SNPs were analyzed, the significance level was set at P < 
1.21 × 10–6 (0.05/41,352 or 0.05/41,372) for the EWASs. 
Quantile-quantile plots either for P values of genotypes 
in the EWASs for eGFR or the serum concentrations of 
creatinine or uric acid or for those of allele frequencies 
in the EWASs for CKD or hyperuricemia are shown 
in Supplementary Figures 6 and 7, respectively. The 
inflation factor (λ) was 1.05 for eGFR, 1.06 for the 
serum concentration of creatinine, 1.05 for the serum 
concentration of uric acid, 1.17 for CKD, and 1.32 for 
hyperuricemia. Multivariable logistic regression analysis 
was performed with CKD as a dependent variable and 
independent variables including age, sex (0, woman; 
1, man), the prevalence of hypertension and diabetes 
mellitus (0, no history of these conditions; 1, positive 
history), and genotype of each SNP. Similar analysis 
was performed with hyperuricemia as a dependent 
variable and independent variables including age, sex, 
and genotype of each SNP. A detailed method of analysis 
was described previously [62]. The relation of genotypes 
of isolated SNPs to eGFR or the serum concentrations 
of creatinine or uric acid was examined by one-way 
ANOVA. Bonferroni’s correction was also applied to 
other statistical analysis as indicated. Statistical tests were 
performed with JMP Genomics version 6.0 software (SAS 
Institute, Cary, NC USA).
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